IL1B and myocardial infarction: The CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) trial assessed the efficacy of the anti-IL1β human monoclonal antibody canakinumab to prevent vascular events in patients with previous history of myocardial infarction and presenting high levels of hsCRP marker.